Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib effects on TRM-like cells in plaque psoriasis
2024-510759-37-00Phase 4Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of deucravacitinib in plaque psoriasis, sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Impact of TYK2 inhibition on TRM-like CD4+ IL-17A-producing T cells after 24 weeks. Started Sep 2024; status: completed.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2024-510759-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510759-37-00.